Teduglutide

Drug Profile

Teduglutide

Alternative Names: ALX-0600; Gattex; Revestive

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda Pharmaceuticals International GmbH
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Preclinical Mucositis
  • Suspended Crohn's disease

Most Recent Events

  • 02 Nov 2016 Shire plans a phase III trial for Short bowel syndrome (In adolescents, In children, In infants, In neonates) in USA (SC) (NCT02954458)
  • 01 Nov 2016 Shire initiated enrolment in a phase III trial for Short bowel syndrome (In adolescents, In children, In infants, In neonates) (SC) (NCT02949362)
  • 08 Jul 2016 Launched for Short bowel syndrome (In adolescents, In children) in United Kingdom (SC), Sweden, Slovakia, Portugal, Netherlands, Malta, Lithuania, Latvia, Ireland, Hungary, Germany, Germany, Finland, Estonia, Denmark, Czech Republic, Norway, Austria and Croatia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top